HUTCHMED has commenced the P-II/III study of its surufatinib (angio-immuno kinase inhibitor) combined with Jiangsu Hengrui’s camrelizumab (PD-1 antibody) for pancreatic ductal adenocarcinoma (PDAC) in China with the first patient dosed on May 08, 2024
The P-II/III study investigates the safety & efficacy of surufatinib (oral) in addition to camrelizumab, nab-paclitaxel & gemcitabine vs nab-paclitaxel + gemcitabine for the 1L treatment of metastatic pancreatic cancer adults (n=500) who did not receive prior systemic anti-tumor therapy
The 1EP of the study includes OS while other endpoints are ORR, PFS, DCR, quality of life, duration of response and time to response
Ref: HUTCHMED | Image: HUTCHMED
Related News:- The US FDA Issued Complete Response Letter to Hutchmed’s Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
